Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Public Citizen Takes Aim At Crestor DTC Ads Defending Statin's Safety

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca's newspaper ads and website contain "false and/or misleading statements about the FDA's current opinion about Crestor," Public Citizen says in letter to Acting Commissioner Crawford. Agency is urged to stop the company's advertising campaign.

You may also be interested in...



Crestor Safety Defense Misrepresents FDA Position, Agency Tells Company

An AstraZeneca “patient safety” print ad that ran in mid-November “misleadingly suggests that the agency does not believe that Crestor poses safety concerns,” the FDA ad division says in an “untitled” letter to the company. The Crestor ad asserted FDA has concluded safety concerns about rosuvastatin “have no medical or scientific basis.”

Crestor Safety Defense Misrepresents FDA Position, Agency Tells Company

An AstraZeneca “patient safety” print ad that ran in mid-November “misleadingly suggests that the agency does not believe that Crestor poses safety concerns,” the FDA ad division says in an “untitled” letter to the company. The Crestor ad asserted FDA has concluded safety concerns about rosuvastatin “have no medical or scientific basis.”

AstraZeneca Refocuses On Risk Management, Elevates Development Oversight

Former Exec VP-Product Strategy & Licensing John Patterson will assume the board-level position of exec director-development effective Jan. 1. Regulatory affairs overhaul will include a review of ongoing Phase III programs for Galida, Cerovive and Symbicort.

Related Content

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel